Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV001195920 | SCV001366344 | uncertain significance | Polycystic kidney disease, adult type | 2016-01-01 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The following ACMG criteria were applied in classifying this variant: PM2. |
Fulgent Genetics, |
RCV001195920 | SCV002801428 | uncertain significance | Polycystic kidney disease, adult type | 2022-03-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV005384969 | SCV006045315 | uncertain significance | Inborn genetic diseases | 2025-02-28 | criteria provided, single submitter | clinical testing | The c.5071G>A (p.G1691S) alteration is located in exon 15 (coding exon 15) of the PKD1 gene. This alteration results from a G to A substitution at nucleotide position 5071, causing the glycine (G) at amino acid position 1691 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Department of Pathology and Laboratory Medicine, |
RCV001195920 | SCV006055015 | uncertain significance | Polycystic kidney disease, adult type | 2022-05-03 | criteria provided, single submitter | research |